We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings
Read MoreHide Full Article
Analysts on Wall Street project that BioMarin Pharmaceutical (BMRN - Free Report) will announce quarterly earnings of $0.57 per share in its forthcoming report, representing an increase of 5.6% year over year. Revenues are projected to reach $660.51 million, increasing 11% from the same quarter last year.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific BioMarin metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus among analysts is that 'Revenues- Net product revenues' will reach $648.62 million. The estimate indicates a change of +10.9% from the prior-year quarter.
The average prediction of analysts places 'Revenues- Royalty and other revenues' at $11.90 million. The estimate indicates a year-over-year change of +12.5%.
Based on the collective assessment of analysts, 'Revenues- Net Product Revenues- VOXZOGO' should arrive at $165.51 million. The estimate points to a change of +46.1% from the year-ago quarter.
Analysts predict that the 'Revenues- Net Product Revenues- ALDURAZYME' will reach $35.01 million. The estimate indicates a year-over-year change of -13.1%.
Analysts forecast 'Revenues- Net Product Revenues- BRINEURA' to reach $42.14 million. The estimate suggests a change of +10.6% year over year.
According to the collective judgment of analysts, 'Revenues- Net Product Revenues- PALYNZIQ' should come in at $81.13 million. The estimate indicates a change of +8.3% from the prior-year quarter.
Analysts expect 'Revenues- Net Product Revenues- KUVAN' to come in at $31.18 million. The estimate indicates a year-over-year change of -38.4%.
The collective assessment of analysts points to an estimated 'Revenues- Net Product Revenues- NAGLAZYME' of $106.25 million. The estimate suggests a change of +17.9% year over year.
It is projected by analysts that the 'Revenues- Net Product Revenues- VIMIZIM' will reach $183.06 million. The estimate points to a change of +3.2% from the year-ago quarter.
BioMarin shares have witnessed a change of +2.6% in the past month, in contrast to the Zacks S&P 500 composite's -0.4% move. With a Zacks Rank #3 (Hold), BMRN is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings
Analysts on Wall Street project that BioMarin Pharmaceutical (BMRN - Free Report) will announce quarterly earnings of $0.57 per share in its forthcoming report, representing an increase of 5.6% year over year. Revenues are projected to reach $660.51 million, increasing 11% from the same quarter last year.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific BioMarin metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus among analysts is that 'Revenues- Net product revenues' will reach $648.62 million. The estimate indicates a change of +10.9% from the prior-year quarter.
The average prediction of analysts places 'Revenues- Royalty and other revenues' at $11.90 million. The estimate indicates a year-over-year change of +12.5%.
Based on the collective assessment of analysts, 'Revenues- Net Product Revenues- VOXZOGO' should arrive at $165.51 million. The estimate points to a change of +46.1% from the year-ago quarter.
Analysts predict that the 'Revenues- Net Product Revenues- ALDURAZYME' will reach $35.01 million. The estimate indicates a year-over-year change of -13.1%.
Analysts forecast 'Revenues- Net Product Revenues- BRINEURA' to reach $42.14 million. The estimate suggests a change of +10.6% year over year.
According to the collective judgment of analysts, 'Revenues- Net Product Revenues- PALYNZIQ' should come in at $81.13 million. The estimate indicates a change of +8.3% from the prior-year quarter.
Analysts expect 'Revenues- Net Product Revenues- KUVAN' to come in at $31.18 million. The estimate indicates a year-over-year change of -38.4%.
The collective assessment of analysts points to an estimated 'Revenues- Net Product Revenues- NAGLAZYME' of $106.25 million. The estimate suggests a change of +17.9% year over year.
It is projected by analysts that the 'Revenues- Net Product Revenues- VIMIZIM' will reach $183.06 million. The estimate points to a change of +3.2% from the year-ago quarter.
View all Key Company Metrics for BioMarin here>>>
BioMarin shares have witnessed a change of +2.6% in the past month, in contrast to the Zacks S&P 500 composite's -0.4% move. With a Zacks Rank #3 (Hold), BMRN is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>